Cipla USA recalls
Cipla USA has 23 recalls on record with the FDA and USDA, the earliest in 2023 and the latest reported on 8 Jul 2026. 21 are still ongoing. 17 were reported in the last 12 months. The most frequent reason is nitrosamine impurity.
Total recalls 23 since 2023
Last 12 months 17 reported
Class I 1 4% of total
Ongoing 21 latest 8 Jul 2026
Recalls per month, last 24 months click a bar for that month
Severity split
Class I 1 4% Class II 18 78% Class III 4 17%
Why cipla usa is recalled
Ongoing cipla usa recalls 21 active
All cipla usa recalls, newest first 23 total
Reported Class Recall Company Reason Where 8 Jul 2026 Drug CLASS II Cinacalcet Hydrochloride Tablets, 60 mg recalled by Cipla USA Cinacalcet Cipla USA Nitrosamine Impurity Nationwide 8 Jul 2026 Drug CLASS II Cinacalcet Hydrochloride Tablets, 90 mg recalled by Cipla USA Cinacalcet Cipla USA Nitrosamine Impurity Nationwide 8 Jul 2026 Drug CLASS II Cinacalcet Hydrochloride Tablets, 30 mg recalled by Cipla USA Cinacalcet Cipla USA Nitrosamine Impurity Nationwide 22 Apr 2026 Drug CLASS II Cinacalcet Hydrochloride Tablets, 60 mg recalled by Cipla USA Cinacalcet Cipla USA Nitrosamine Impurity Nationwide 22 Apr 2026 Drug CLASS II Cinacalcet Hydrochloride Tablets, 90 mg recalled by Cipla USA Cinacalcet Cipla USA Nitrosamine Impurity Nationwide 22 Apr 2026 Drug CLASS II Cinacalcet Hydrochloride Tablets, 30 mg recalled by Cipla USA Cinacalcet Cipla USA Nitrosamine Impurity Nationwide 15 Apr 2026 Drug CLASS II Lanreotide Injection, 120 mg* recalled by Cipla USA Lanreotide Acetate Cipla USA Sterility Nationwide 15 Apr 2026 Drug CLASS II Lanreotide Injection, 120 mg recalled by Cipla USA Lanreotide Acetate Cipla USA Sterility Nationwide 11 Mar 2026 Drug CLASS III Nilotinib Capsules recalled by Cipla USA Nilotinib Cipla USA Potency & Assay Nationwide 11 Mar 2026 Drug CLASS III Nilotinib Capsules recalled by Cipla USA Nilotinib Cipla USA Potency & Assay Nationwide 28 Jan 2026 Drug CLASS III Diclofenac Sodium Topical Gel recalled by Cipla USA Diclofenac Sodium Cipla USA Other Nationwide 21 Jan 2026 Drug CLASS II Lanreotide Injection, 120 mg/ per pre-filled syringe recalled Lanreotide Acetate Cipla USA Particulate Matter Nationwide 17 Dec 2025 Drug CLASS II Cinacalcet Hydrochloride Tablets, 60 mg recalled by Cipla USA Cinacalcet Cipla USA Nitrosamine Impurity Nationwide 17 Dec 2025 Drug CLASS II Lanthanum Carbonate chewable tablets, 1000mg* recalled by Cipla USA Lanthanum Carbonate Cipla USA Potency & Assay Nationwide 17 Dec 2025 Drug CLASS II Cinacalcet Hydrochloride Tablets, 30 mg recalled by Cipla USA Cinacalcet Cipla USA Nitrosamine Impurity Nationwide 17 Dec 2025 Drug CLASS II Cinacalcet Hydrochloride Tablets, 90 mg recalled by Cipla USA Cinacalcet Cipla USA Nitrosamine Impurity Nationwide 17 Dec 2025 Drug CLASS II Lanthanum Carbonate chewable tablets, 1000mg* recalled by Cipla USA Lanthanum Carbonate Cipla USA Potency & Assay Nationwide 27 Aug 2025 Drug CLASS III Albuterol Sulfate, Inhalation Aerosol, 90 mcg recalled by Cipla USA Albuterol Sulfate Cipla USA Potency & Assay Nationwide 30 Jul 2025 Drug CLASS II Budesonide Inhalation Suspension, 0.5mg/-dose ampules per, five recalled Budesonide Cipla USA Sterility Nationwide 20 Nov 2024 Drug CLASS II Lanthanum Carbonate Chewable Tablets, 1000mg recalled by Cipla USA Cipla USA Other Nationwide 20 Nov 2024 Drug CLASS II Lanthanum Carbonate Chewable Tablets, 1000mg recalled by Cipla USA Cipla USA Other Nationwide 1 May 2024 Drug CLASS II Ipratropium Bromide and Albuterol Sulfate Inhalation recalled Ipratropium Bromide And Albuterol Sulfate Cipla USA Packaging Defects Nationwide 19 Jul 2023 Drug CLASS I Albuterol Sulfate Inhalation Aerosol, 90 mcg recalled by Cipla USA Albuterol Sulfate Cipla USA Packaging Defects Nationwide
About this list
Records come from FDA enforcement reports and USDA FSIS notices, grouped by normalised name. A company operating under several names may appear more than once.